Patricia Andrade, MD
Surgery · Fairhaven, MANPI 1417956426
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $2,500 of the $3,889 with a category attached, or 64.3%. AbbVie accounts for 70.5% of it on its own, with 20 other manufacturers making up the rest. Reporting peaked in 2023 at $1,998 and has fallen 99.4% since, to $13 in 2025.
Across 61 payments — averaging $63.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- Johnson & Johnson$262
- Smith+Nephew$133
- Kerecis Limited$111
- TELA Bio, Inc.$89
- Medtronic$74
- plus $477 from 15 others
What the payments were for
- Speaking & faculty fees$2,50064%
- Food & beverage$1,33234%
- Education$571%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 13 | $2,742 |
| Johnson & Johnson(3 entities) | 12 | $262 |
| Smith+Nephew | 6 | $133 |
| Kerecis Limited | 4 | $111 |
| TELA Bio, Inc. | 4 | $89 |
| Medtronic(2 entities) | 3 | $74 |
| Viiv Healthcare Company | 3 | $73 |
| Cook Medical LLC | 1 | $60 |
| TEI Biosciences Inc | 2 | $42 |
| Teleflex LLC | 1 | $37 |
| Integra Lifesciences Corporation | 1 | $34 |
| W. L. Gore & Associates, Inc. | 1 | $34 |
| Convatec Inc. | 1 | $32 |
| Astellas Pharma US Inc | 1 | $31 |
| Paratek Pharmaceuticals, Inc. | 2 | $28 |
| Gilead | 1 | $25 |
| Melinta Therapeutics, LLC | 1 | $20 |
| Misonix Inc | 1 | $17 |
| Braintree Laboratories, Inc. | 1 | $15 |
| Bard Peripheral Vascular, Inc. | 1 | $15 |
| Merck | 1 | $13 |
How this compares
$3,889 in reported general payments places this provider in the 70th percentile of 694 surgery providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ibuprofen | 20 | $82 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 13 | $51 |
| Tramadol Hcl | 18 | $38 |
Paid to pharmacies, not to this prescriber.
Other surgery in Fairhaven
- Michael TarnoffBoston$1.4M
- Omar KudsiBoston$886K
- Philip CohenBrockton$280K
- Ankit MehtaBoston$278K
- Mark ConradMethuen$187K
- James HermenegildoFall River$178K
- Richard EngelmanSpringfield$167K
- Reuben ShinBurlington$158K
- Richard BirkettBeverly$93K
- Johannes KratzBoston$79K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.